Sponsor

Weill Cornell Medical College in Qatar

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Weill Cornell Medical College in Qatar appears in 19 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials19
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

19 shown
Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood PressureNCT05903950 · lead sponsor · 2024-11-03
RECRUITING
Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 DiabetesNCT07556497 · lead sponsor · 2020-11-17
RECRUITING
Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial IntelligenceNCT07515807 · lead sponsor · 2026-07-16
NOT_YET_RECRUITING
Qatar Cardiometabolic CohortNCT07675928 · lead sponsor · 2026-06-01
NOT_YET_RECRUITING
Earlier Diagnosis of Peripheral Neuropathy Using A Simple sCreening Tool (ACT)NCT07163000 · lead sponsor · 2025-05-11
ACTIVE_NOT_RECRUITING
Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in RamadanNCT03349840 · lead sponsor · 2018-01-07
TERMINATED
Diabetes Intervention Accentuating Diet and Enhancing MetabolismNCT03225339 · lead sponsor · 2017-07-16
COMPLETED
HbA1c Variability in Type II DiabetesNCT02879409 · lead sponsor · 2016-11-01
ACTIVE_NOT_RECRUITING
Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)NCT02410005 · lead sponsor · 2014-10-01
TERMINATED
Qatar Universal Diabetes Outcomes (QUDOS) StudyNCT02660476 · lead sponsor · 2014-10-01
TERMINATED
An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 DiabetesNCT03216564 · collaborator · 2017-05-10
UNKNOWN
Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari PopulationNCT02316522 · collaborator · 2014-10-23
COMPLETED
Depression, Obesity and Inflammatory MarkersNCT02765100 · collaborator · 2014-10-01
COMPLETED
Biologic Basis Of Increased Susceptibility Of Smokers To Pulmonary Infection With Mycobacterium TuberculosisNCT02021747 · collaborator · 2014-01-01
WITHDRAWN
Genetic Contribution to the Pathophysiology of the Charcot Foot in Qatari Patients With DiabetesNCT02316483 · collaborator · 2013-12-01
COMPLETED
DNA Methylation and Gene Expression in Qataris With Type 2 DiabetesNCT02021695 · collaborator · 2013-09-01
COMPLETED
Collection of Blood for Gene Expression/Genomic Studies in Individuals With Diabetes (Qatar)NCT01172743 · collaborator · 2009-06-01
TERMINATED
Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar)NCT00504361 · collaborator · 2006-05-01
COMPLETED
Lung Disease Collection (Qatar): Evaluation of the Lungs of Individuals With Lung DiseaseNCT00504738 · collaborator · 2006-04-01
COMPLETED

Drugs studied in this sponsor's trials

11 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Weill Cornell Medical College in Qatar as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
calcitriol1
dapagliflozin1
gliclazide1
insulin glargine1
insulin, regular, human1
liraglutide1
losartan1
metformin1

Sponsor roles

lead sponsor10
collaborator9
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.